Trametinib Kinase Inhibitor Yibasiye BRAF V600 Kanseri ihinduka-nziza

Igiciro cyerekana: USD 8-15 / g

izina RY'IGICURUZWA Trametinib
URUBANZA No. 871700-17-3
MF C26H23FIN5O4
MW 615.402623
Ubucucike 1.743
Ingingo yo gushonga 293-303 ° C.

Twandikire

ibicuruzwa birambuye

Ibisobanuro birambuye

Trametinib ni inhibitor ya kinase ikomeye kandi ihitamo ikoreshwa cyane cyane mukuvura melanoma idashobora gukemurwa cyangwa metastatike hamwe na mutation ya BRAF V600, hamwe nubwoko bwihariye bwa kanseri yibihaha yateye imbere cyangwa metastatike. Iyi ngingo irasobanura uburyo bwibikorwa, ibimenyetso byubuvuzi, ninyungu za trametinib mu kuvura kanseri ya BRAF V600.

I. Gusobanukirwa Trametinib:

A. Umunwa, imbaraga, no guhitamo kinase inhibitor

B. Biri mubyiciro bya MEK inhibitor

C. Hagarika ibikorwa bya kinase bya MEK1 na MEK2

D. Irabuza epfo na ruguru ERK1 na ERK2

II. Ibimenyetso bya Clinical:

A. Melanoma idashobora gukemurwa cyangwa metastatike ibika mutation ya BRAF V600:

Ubuvuzi bwo kuvura hamwe na dabrafenib mesylate

B. Ubuvuzi bwa nyuma yubuvuzi bwa BRAF V600 mutation-nziza ya melanoma:

Kuvura adjuvant hamwe na dabrafenib mesylate nyuma yo kwangwa burundu

III. Uruhare muri Kanseri y'ibihaha itari nto:

A. Kanseri y'ibihaha itari ntoya nk'impamvu nyamukuru itera uburwayi n'impfu

B. Igipimo cya mutation ya BRAF no gukwirakwira kwa BRAF V600E

C. Ingaruka zo kubuza Trametinib kuri selile BRAF V600 ihinduka-nziza ya melanoma

IV. Uburyo bwibikorwa:

A. Kubuza guhindurwa kwa mitogen-ikora ibimenyetso bidasanzwe-bigengwa na kinase (MEK) 1 na MEK2

B. Ingaruka kumuhanda MAPK na proteine ya MEK

C. Kubuza gukwirakwiza selile no kumanuka ERK inzira

V. Ubuvuzi bwa Adjuvant Ubuvuzi:

A. Inyungu zo kuvura hamwe na Dabrafenib na Trametinib

B. Kurokoka igihe kirekire, kuramba bidasubirwaho kubaho (RFS) inyungu mubyiciro byinshi ibyago III BRAF ihindagurika-nziza ya melanoma abarwayi.

Trametinib, inhibitor ya kinase inhibitor, yerekana akamaro gakomeye mukuvura kanseri ya BRAF V600 ihindagurika cyane cyane melanoma idashobora gukemurwa cyangwa metastatike hamwe nubwoko bwihariye bwa kanseri yibihaha itari mito. Uburyo bwibikorwa byayo, kubuza ibikorwa bya MEK1 na MEK2 kinase, biganisha kumanuka ERK inzira yo kubuza no guhagarika ikwirakwizwa rya selile. Trametinib, ifatanije na mesabate ya dabrafenib, itanga inyungu zo kuvura haba murwego rwo hejuru kandi ruhuza abarwayi ba BRAF V600 mutation-nziza ya melanoma.
Twandikire kugirango tugire inama kumiti namakuru menshi yo kugiciro kugirango twongere ubuvuzi.